Quantum Biotech Early Stage(SRL)

BE 0789.524.966

Financial data from Quantum Biotech Early Stage

	2023
Profit/Loss Section 9904: Profit/Loss of the financial year (after taxes on result) (+/-)	€ 345
Equity Section 10/15: Equity consists of capital, capital reserves and earnings that remain within the company. These are fully owned by the company and are at its disposal to cover its risks. The better the ratio between equity and debts, the more solvent a company is. A positive equity ratio is important. A negative equity ratio (because of accumulated losses) is a severe warning sign that the continuity of the company may be threatened.	€ 250.345
Gross margin Section 9900: Gross margin or added value is net sales minus the direct costs of the goods sold. In other words: sales invoices minus purchase invoices (70/74 – 60/61). A negative gross margin is a warning sign especially when occurring over several years. It may indicate that the company has insufficient means to cover internal costs like salaries, etc.	€ 3.159

Publications in the Belgian Official Journal from Quantum Biotech Early Stage

	Date	Publication
	11-08-2022	Rubric Constitution (New Juridical Person, Opening Branch, etc...) (NL)

Frequently asked questions

What is the VAT number of Quantum Biotech Early Stage?

The VAT number of Quantum Biotech Early Stage is BE0789524966.

When was Quantum Biotech Early Stage founded?

Quantum Biotech Early Stage was founded on 09-08-2022.

What is the address of Quantum Biotech Early Stage?

The current registered office of Quantum Biotech Early Stage is located at Stapsteenweg(Heu) 1/a, 9070 Destelbergen.

When was the last time Quantum Biotech Early Stage filed their annual financial statements?

The most recent financial statements of Quantum Biotech Early Stage were filed on 07-08-2024. You can view them here.

How many employees does Quantum Biotech Early Stage have?

There are currently no employees working at Quantum Biotech Early Stage or no workforce information is available.

What is the annual turnover of Quantum Biotech Early Stage?

At the time of its most recent financial statements, Quantum Biotech Early Stage did not publish any turnover figures. Quantum Biotech Early Stage reported a gross margin of €3,159.31.